Post-Traumatic Stress Disorder (PTSD) is a severe mental health condition triggered by experiencing or witnessing traumatic events. According to the World Health Organization (WHO), an estimated 3.9% of the global population has experienced PTSD at some stage in life. As per the Post-Traumatic Stress Disorder (PTSD) Pipeline Analysis by Expert Market Research, the market is witnessing significant advancements driven by the development of novel psychotherapies, antidepressants, and neurostimulation therapies. Increasing awareness, ongoing clinical trials, and growing research on targeted treatments are expected to accelerate market growth in the coming years, offering improved therapeutic outcomes for patients worldwide.
The Post-Traumatic Stress Disorder (PTSD) Drug Pipeline Report by Expert Market Research gives comprehensive insights into ongoing post-traumatic stress disorder (PTSD) clinical trials. It covers various aspects related to the details of each of these drugs under development for post-traumatic stress disorder (PTSD). The report includes the analysis of over 100 pipeline drugs and 50+ companies. The post-traumatic stress disorder (PTSD) pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from post-traumatic stress disorder (PTSD).
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing post-traumatic stress disorder (PTSD) pipeline development activities are covered. Moreover, post-traumatic stress disorder (PTSD) collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Post-traumatic stress disorder (PTSD) is a mental health condition that develops after a traumatic event. The symptoms of this disorder involve anxiety, flashbacks, negative thoughts and beliefs, and hypervigilance among others. People who go through traumatic events may have temporary difficulty in adjusting and coping. Moreover, if the symptoms get worse and interfere with day-to-day functioning, it can develop into PTSD. The symptoms of PTSD may start within one month of a traumatic event. It can interfere with the ability to do normal daily tasks. Generally, post-traumatic stress disorder (PTSD) symptoms are grouped into four types, including, intrusive memories, negative changes in thinking and mood, avoidance, and changes in physical and emotional reactions.
There are two types of post-traumatic stress disorder (PTSD) including acute stress disorder and complex PTSD (CPTSD). Acute stress disorder is a short-term mental health condition which can occur within the first month after experiencing a traumatic event. Complex PTSD is a mental health condition which can develop if a person experiences chronic trauma which includes long-term child physical or sexual abuse, long-term domestic violence and war among others.
The primary post-traumatic stress disorder (PTSD) treatment includes psychotherapy (talk therapy), especially forms of cognitive behavioral therapy (CBT). The specific forms of CBT include cognitive processing therapy, eye movement desensitization and reprocessing (EMDR) therapy, group therapy, prolonged exposure therapy and trauma-focused CBT. Currently, there are no medications approved by the Food and Drug Administration (FDA) for the treatment of post-traumatic stress disorder (PTSD). However, healthcare providers prescribe certain medications including antidepressants like selective serotonin reuptake inhibitors (SSRIs) or serotonin and norepinephrine reuptake inhibitors (SNRIs) and anti-anxiety medications.
Several pharma companies are developing innovative treatments to manage post-traumatic stress disorder (PTSD). There has been a significant growth in the treatment options for the condition. Positive results from clinical trials during the past decade of medication-assisted psychotherapy are providing hope to manage the disease effectively.
Around 3.9% of people worldwide are estimated to experience post-traumatic stress disorder (PTSD) at some point in their lives. However, this number rises sharply in individuals exposed to violent conflict or war, with rates reported to be as high as 15.3%—nearly three times higher than the global average. The risk is also significantly higher following experiences of sexual violence. In the general population, about 6 in every 100 adults are likely to develop PTSD during their lifetime, with women being twice as likely as men to be affected. Complex PTSD, a more severe form, is estimated to impact between 1% and 8% of people globally.
This section of the report covers the analysis of post-traumatic stress disorder (PTSD) drug candidates based on several segmentations including:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
By Drug Class
EMR’s post-traumatic stress disorder (PTSD) therapeutics assessment report covers 50+ drug analyses based on drug classes:
By Route of Administration
EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for post-traumatic stress disorder (PTSD).
The PTSD drug pipeline includes a total of 466 drugs at various stages of development. Phase 2 holds the largest share, making up about 40% of the pipeline, followed by Phase 1 at 21%. Phase 3 accounts for 18%, while Phase 4 represents around 16%. Early Phase 1 makes up the smallest portion, with just 5%. This distribution shows a strong emphasis on mid-stage clinical research for PTSD treatments.
The drug molecules categories covered under post-traumatic stress disorder (PTSD) pipeline analysis include recombinant fusion proteins, small molecules, monoclonal antibodies, peptides, polymer, and gene therapy. Currently under phase II, Jazz Pharmaceuticals is developing an investigational small molecule drug called JZP150 to treat post-traumatic stress disorder (PTSD) in adults. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for post-traumatic stress disorder (PTSD).
The EMR post-traumatic stress disorder (PTSD) drug report insights involve the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in PTSD clinical trials:
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for post-traumatic stress disorder (PTSD). It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of post-traumatic stress disorder (PTSD) drug candidates.
The trial is designed to evaluate the safety and effectiveness of administering 10 mg of balovaptan orally once a day in comparison to a similar placebo in adults with post-traumatic stress disorder (PTSD). The trial is sponsored by Hoffmann-La Roche and is currently under phase II.
The objective of the study is to assess the clinical safety and effectiveness of ZP150 in the treatment of adults with post-traumatic stress disorder (PTSD). The trial is sponsored by Jazz Pharmaceuticals and is currently under phase II.
Boehringer Ingelheim is developing this drug and is currently under phase II. The study is being conducted to find out whether the drug improves symptoms in post-traumatic stress disorder (PTSD) affected patients.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Post-Traumatic Stress Disorder (PTSD) Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for post-traumatic stress disorder (PTSD). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into post-traumatic stress disorder (PTSD) collaborations, regulatory environments, and potential growth opportunities within the treatment landscape.
Post Traumatic Stress Disorder (PTSD) Market
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| Scope of the Report | Details |
| Drug Pipeline by Clinical Trial Phase |
|
| Route of Administration |
|
| Drug Classes |
|
| Leading Sponsors Covered |
|
| Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share